1. Immunotherapy of M2 macrophage derived from exosome-based nanoparticles for spinal cord injury.
- Author
-
Bai, Lu, Gao, Jinpeng, Zhang, Peng, Lin, Sen, and Zhang, Chuanjie
- Subjects
- *
SPINAL cord injuries , *IMMUNOTHERAPY , *MICROGLIA , *PRUSSIAN blue , *NANOPARTICLES , *APOPTOSIS inhibition , *MACROPHAGES - Abstract
• E-MPBs shows sustained cellular uptake by microglia. • E-MPBs exhibits anti-ROS and anti-inflammation properties against M1 microglia. • E-MPBs develops a novel nanoplatform for SCI. Developing biomimetic nanoparticles without off-target side-effects remains a major challenge in spinal cord injury (SCI) immunotherapy. In this paper, we have conducted a drug carrier which is biocompatible macrophages-exocytosed exosome-biomimetic manganese (Mn)-iron prussian blue analogues (MPBs) for SCI immunotherapy. Exosome-sheathed MPBs (E-MPBs) exhibit promoted microglia accumulation, alleviation from H 2 O 2 -induced microenvironment and inhibition of apoptosis and inflammation in vitro. In addition, E-MPBs possessed significant tissue repair and neuroprotection in vivo. These properties endowed E-MPBs with great improvement in vivo in function recovery, resulting in anti-neuroinflammation activity and excellent biocompatibility in mice SCI model. As a promising treatment for efficient SCI immunotherapy, these results demonstrate the use of exosome-sheathed biomimetic nanoparticles exocytosed by anti-inflammation cells is feasible. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF